Age Related Macular Degeneration - Pipeline Review, H1 2017

Published: Jun, 2017 | Pages: 527 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration - Pipeline Review, H1 2017, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape.

Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Age Related Macular Degeneration - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 31, 19, 4, 121, 30 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 15 and 3 molecules, respectively.

Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Age Related Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Age Related Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Age Related Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 7
Age Related Macular Degeneration - Overview 8
Age Related Macular Degeneration - Therapeutics Development 9
Age Related Macular Degeneration - Therapeutics Assessment 36
Age Related Macular Degeneration - Companies Involved in Therapeutics Development 50
Age Related Macular Degeneration - Drug Profiles 108
Age Related Macular Degeneration - Dormant Projects 476
Age Related Macular Degeneration - Discontinued Products 487
Age Related Macular Degeneration - Product Development Milestones 489
Appendix 503

List of Tables

Number of Products under Development for Age Related Macular Degeneration, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Age Related Macular Degeneration - Pipeline by 3SBio Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Abzena Plc, H1 2017
Age Related Macular Degeneration - Pipeline by Achillion Pharmaceuticals Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Aciont Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Acucela Inc, H1 2017
Age Related Macular Degeneration - Pipeline by AdAlta Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Adverum Biotechnologies Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Aerie Pharmaceuticals Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Aerpio Therapeutics Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Alcon Laboratories Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Alimera Sciences Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Alkeus Pharmaceuticals Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Allergan Plc, H1 2017
Age Related Macular Degeneration - Pipeline by Allinky Biopharma, H1 2017
Age Related Macular Degeneration - Pipeline by Alteogen Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Amakem NV, H1 2017
Age Related Macular Degeneration - Pipeline by Amarna Therapeutics BV, H1 2017
Age Related Macular Degeneration - Pipeline by Apellis Pharmaceuticals Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Apexigen Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Applied Genetic Technologies Corp, H1 2017
Age Related Macular Degeneration - Pipeline by Astellas Pharma Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Benitec Biopharma Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Biokine Therapeutics Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Biomar Microbial Technologies, H1 2017
Age Related Macular Degeneration - Pipeline by BioMAS Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Biomics Biotechnologies Co Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Biophytis SAS, H1 2017
Age Related Macular Degeneration - Pipeline by BLR Bio LLC, H1 2017
Age Related Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Age Related Macular Degeneration - Pipeline by Caladrius Biosciences Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Catalyst Biosciences Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Cell Cure Neurosciences Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Cell Medica Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Charlesson LLC, H1 2017
Age Related Macular Degeneration - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
Age Related Macular Degeneration - Pipeline by Cipla Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by CJ HealthCare Corp, H1 2017
Age Related Macular Degeneration - Pipeline by Clanotech AB, H1 2017
Age Related Macular Degeneration - Pipeline by Coherus BioSciences Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Colby Pharmaceutical Company, H1 2017
Age Related Macular Degeneration - Pipeline by Crinetics Pharmaceuticals Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Critical Pharmaceuticals Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Diffusion Pharmaceuticals Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Elsalys Biotech SAS, H1 2017
Age Related Macular Degeneration - Pipeline by Exonate Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by EyeGate Pharmaceuticals Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Eyevensys SAS, H1 2017
Age Related Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by FirstString Research Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Formycon AG, H1 2017
Age Related Macular Degeneration - Pipeline by Gene Techno Science Co Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Genentech Inc, H1 2017
Age Related Macular Degeneration - Pipeline by GenSight Biologics SA, H1 2017
Age Related Macular Degeneration - Pipeline by GlaxoSmithKline Plc, H1 2017
Age Related Macular Degeneration - Pipeline by Graybug Vision Inc, H1 2017
Age Related Macular Degeneration - Pipeline by HanAll Biopharma Co Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Huabo Biopharm Co Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by iCo Therapeutics Inc., H1 2017
Age Related Macular Degeneration - Pipeline by Icon Bioscience Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Iconic Therapeutics Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Inception Sciences Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Innovent Biologics Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Intellect Neurosciences Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Johnson & Johnson, H1 2017
Age Related Macular Degeneration - Pipeline by Just Biotherapeutics Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Kala Pharmaceuticals Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Kodiak Sciences Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Lead Discovery Center GmbH, H1 2017
Age Related Macular Degeneration - Pipeline by LeadArtis SL, H1 2017
Age Related Macular Degeneration - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Lupin Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by M's Science Corp, H1 2017
Age Related Macular Degeneration - Pipeline by Mabion SA, H1 2017
Age Related Macular Degeneration - Pipeline by MacuCLEAR Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Mitotech SA, H1 2017
Age Related Macular Degeneration - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
Age Related Macular Degeneration - Pipeline by Mor Research Application Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Navya Biologicals Pvt Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Neovacs SA, H1 2017
Age Related Macular Degeneration - Pipeline by Neumedicines Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Novartis AG, H1 2017
Age Related Macular Degeneration - Pipeline by NovelMed Therapeutics Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Ocular Therapeutix Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Ohr Pharmaceutical Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Omeros Corp, H1 2017
Age Related Macular Degeneration - Pipeline by Ophthotech Corp, H1 2017
Age Related Macular Degeneration - Pipeline by Oxford BioMedica Plc, H1 2017
Age Related Macular Degeneration - Pipeline by PanOptica Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2017
Age Related Macular Degeneration - Pipeline by Pfenex Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Pfizer Inc, H1 2017
Age Related Macular Degeneration - Pipeline by PlantForm Corp, H1 2017
Age Related Macular Degeneration - Pipeline by Promedior Inc, H1 2017
Age Related Macular Degeneration - Pipeline by pSivida Corp, H1 2017
Age Related Macular Degeneration - Pipeline by Ra Pharmaceuticals Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Age Related Macular Degeneration - Pipeline by RegenxBio Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Ribomic Inc, H1 2017
Age Related Macular Degeneration - Pipeline by RXi Pharmaceuticals Corp, H1 2017
Age Related Macular Degeneration - Pipeline by Samumed LLC, H1 2017
Age Related Macular Degeneration - Pipeline by SanBio Inc, H1 2017
Age Related Macular Degeneration - Pipeline by SciFluor Life Sciences LLC, H1 2017
Age Related Macular Degeneration - Pipeline by Stealth BioTherapeutics Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
Age Related Macular Degeneration - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Tyrogenex Inc, H1 2017
Age Related Macular Degeneration - Pipeline by Wellstat Ophthalmics Corp, H1 2017
Age Related Macular Degeneration - Pipeline by Xbrane Biopharma AB, H1 2017
Age Related Macular Degeneration - Dormant Projects, H1 2017
Age Related Macular Degeneration - Dormant Projects, H1 2017 (Contd..1), H1 2017
Age Related Macular Degeneration - Dormant Projects, H1 2017 (Contd..2), H1 2017
Age Related Macular Degeneration - Dormant Projects, H1 2017 (Contd..3), H1 2017
Age Related Macular Degeneration - Dormant Projects, H1 2017 (Contd..4), H1 2017
Age Related Macular Degeneration - Dormant Projects, H1 2017 (Contd..5), H1 2017
Age Related Macular Degeneration - Dormant Projects, H1 2017 (Contd..6), H1 2017
Age Related Macular Degeneration - Dormant Projects, H1 2017 (Contd..7), H1 2017
Age Related Macular Degeneration - Dormant Projects, H1 2017 (Contd..8), H1 2017
Age Related Macular Degeneration - Dormant Projects, H1 2017 (Contd..9), H1 2017
Age Related Macular Degeneration - Discontinued Products, H1 2017
Age Related Macular Degeneration - Discontinued Products, H1 2017 (Contd..1), H1 2017